Business Description
Ascentage Pharma Group International
ISIN : KYG0519B1023
Total Employee Number:
767Compare
Compare
Traded in other countries / regions
06855.Hong KongAAPG.USA36X0.Germany IPO Date
2020-12-29Description
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.25 | |||||
Equity-to-Asset | 0.33 | |||||
Debt-to-Equity | 1.5 | |||||
Debt-to-EBITDA | -1.72 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -0.52 | |||||
Beneish M-Score | 0.65 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 26.1 | |||||
3-Year EBITDA Growth Rate | -1.3 | |||||
3-Year EPS without NRI Growth Rate | -0.4 | |||||
3-Year FCF Growth Rate | 0.4 | |||||
3-Year Book Growth Rate | 31.6 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 57.17 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-1 Month Momentum % | -40.57 | |||||
6-1 Month Momentum % | -40.57 | |||||
12-1 Month Momentum % | -13.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.79 | |||||
Quick Ratio | 1.77 | |||||
Cash Ratio | 1.5 | |||||
Days Inventory | 108.64 | |||||
Days Sales Outstanding | 87.44 | |||||
Days Payable | 781.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.1 | |||||
Shareholder Yield % | -23.73 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 91.48 | |||||
Operating Margin % | -208.49 | |||||
Net Margin % | -216.31 | |||||
EBITDA Margin % | -201.42 | |||||
FCF Margin % | 39.95 | |||||
OCF Margin % | 41.27 | |||||
ROE % | -165.7 | |||||
ROA % | -39.02 | |||||
ROIC % | -57.65 | |||||
3-Year ROIIC % | -62.81 | |||||
ROC (Joel Greenblatt) % | -136.85 | |||||
ROCE % | -64.03 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 74.26 | |||||
PS Ratio | 17.69 | |||||
PB Ratio | 7.96 | |||||
Price-to-Tangible-Book | 8.55 | |||||
Price-to-Free-Cash-Flow | 38.78 | |||||
Price-to-Operating-Cash-Flow | 37.52 | |||||
EV-to-EBIT | -8.71 | |||||
EV-to-EBITDA | -8.9 | |||||
EV-to-Revenue | 17.92 | |||||
EV-to-Forward-Revenue | 10.49 | |||||
EV-to-FCF | 45.04 | |||||
Price-to-GF-Value | 0.69 | |||||
| Price-to-Net-Current-Asset-Value | 34.85 | |||||
Earnings Yield (Greenblatt) % | -11.48 | |||||
FCF Yield % | 2.16 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ASPHF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ascentage Pharma Group International Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 80.88 | ||
| EPS (TTM) ($) | -0.491 | ||
| Beta | 0.475 | ||
| 3-Year Sharpe Ratio | 0.33 | ||
| 3-Year Sortino Ratio | 0.95 | ||
| Volatility % | 97.47 | ||
| 14-Day RSI | - | ||
| 14-Day ATR ($) | 0.061705 | ||
| 20-Day SMA ($) | 4.674 | ||
| 12-1 Month Momentum % | -13.48 | ||
| 52-Week Range ($) | 4.53 - 10.65 | ||
| Shares Outstanding (Mil) | 373.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ascentage Pharma Group International Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ascentage Pharma Group International Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-08-21 08:00 | In 58 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 19:00 | In 57 days | ||
| Jefferies Global Healthcare Conference | 2026-06-03 08:10 | 5.04 (+0.00%) | ||
| General meeting for 2026 | 2026-05-20 10:00 | 8.48 (+0.00%) | ||
| Guidance call for 2026 | 2026-05-19 10:30 | 8.48 (+0.00%) | ||
| B. Riley Commercial/Late-Stage Oncology Best Ideas Summit | 2026-05-18 | 8.48 (+0.00%) | ||
| Annual report for 2025 | 2026-04-28 | 8.48 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-26 08:00 | 8.48 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-25 19:00 | 8.48 (+0.00%) | ||
| TD Cowen 46th Annual Health Care Conferenc | 2026-03-04 09:50 | 8.48 (+0.00%) |
Show
Entries
Ascentage Pharma Group International Frequently Asked Questions
What is Ascentage Pharma Group International(ASPHF)'s stock price today?
The current price of ASPHF is $4.53. The 52 week high of ASPHF is $10.65 and 52 week low is $4.53.
When is next earnings date of Ascentage Pharma Group International(ASPHF)?
The next earnings date of Ascentage Pharma Group International(ASPHF) is 2026-08-20 Est..
Does Ascentage Pharma Group International(ASPHF) pay dividends? If so, how much?
Ascentage Pharma Group International(ASPHF) does not pay dividend.
Guru Commentaries on OTCPK:ASPHF
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Ascentage Pharma Group International
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers